Connect with us

Business

Eli Lilly gaining in GLP-1 market over Novo Nordisk, earnings show

Published

on

Eli Lilly gaining in GLP-1 market over Novo Nordisk, earnings show

The Eli Lilly and Novo Nordisk logos.

Mike Blake | Tom Little | Reuters

It’s a tale of two drugmakers in the red-hot obesity drug market. 

Advertisement

Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, Lilly sees revenue jumping again thanks to its blockbuster medicines. 

The split in guidance — despite similar headwinds — underscores the strength of Lilly’s position in the obesity and diabetes drug market, underpinned by its more effective injections and early foray into direct-to-consumer sales, among other factors. While Novo Nordisk effectively made the drugs mainstream, Lilly has since taken a clear edge in market share — and the forecasts show it will likely only extend its advantage this year.

“The difference in sales momentum and market share trend was visible throughout 2025, but the dichotomy between the two companies’ prospects was accentuated within this 24-hour period in which Novo guided below consensus and Lilly guided above consensus expectations,”  Leerink Partners analyst David Risinger told CNBC on Wednesday. 

“That really solidified an investor’s mind that Lilly is going to be the dominant player in obesity going forward,” he added. 

Advertisement

This year, all eyes will be on how Lilly’s upcoming obesity pill, orforglipron, fares against Novo’s own oral Wegovy drug, which has had an explosive U.S. launch this year.

In an interview on CNBC’s “Squawk Box” on Wednesday, Lilly CEO David Ricks said 20 million to 25 million patients are currently taking both companies’ medicines. But he said the total addressable market of patients in the obesity space is “gigantic.” 

Eli Lilly CEO David Ricks on Q4 results: We're the market leader in both diabetes and obesity now

Diverging outlooks

On Wednesday, Lilly forecasted 2026 sales of $80 billion to $83 billion, surpassing the $77.62 billion that analysts were expecting, according to LSEG. 

The midpoint of that outlook translates to sales growing by 25% this year.

In contrast, Novo warned on Tuesday that it sees sales and profit declining by 5% to 13% this year, as prices fall in the U.S. and exclusivity expires for its blockbuster obesity and diabetes drugs in China, Brazil and Canada. 

Advertisement

Mike Doustdar, left, CEO of Novo Nordisk, and David Ricks, CEO of Eli Lilly, listen as President Donald Trump speaks in the Oval Office during an event about weight-loss drugs on Nov. 6, 2025.

Andrew Caballero-Reynolds | Afp | Getty Images

Lilly similarly pointed to a “global pricing decline in the low- to mid- teens [percentages] this year.” That comes after the landmark “most favored nation” deals both companies struck with President Donald Trump in November to slash obesity and diabetes drug costs, along with their recent efforts to further reduce direct-to-consumer prices for their treatments. 

The agreements with Trump are expected to take a bite out of both companies’ sales, but eventually increase volumes of prescriptions for their drugs. Still, Lilly is bullish about other factors that will help offset that pricing pressure. 

Advertisement

That includes continued worldwide demand for its obesity drug Zepbound and diabetes counterpart Mounjaro and the expected launch of its GLP-1 pill for obesity in the second quarter, pending U.S. approval. Lilly also pointed to government Medicare coverage of obesity treatments starting for the first time by at least July, one of the winning features of the drug pricing deals with Trump. 

Lilly’s Ricks told CNBC that coverage will open up access to 40 million new Medicare beneficiaries, “and that could be quite expansive to volume.”

Overall, Risinger called Lilly’s guidance “very encouraging” and said the “price per volume trade-off is playing out well” for the company.

He said tirzepatide, the active ingredient in Zepbound and Mounjaro, is “superior” in its effectiveness and tolerability compared to semaglutide, the ingredient in Novo’s obesity and diabetes drugs. That was proven in a head-to-head clinical trial conducted by Lilly in 2024, and prescription trends show that the company’s drugs are preferred among prescribers.  

Advertisement

“I think that’s what is driving Lilly’s market share gain” relative to Novo, Risinger said. 

Another factor that sets Lilly and Novo apart is patent exclusivity. While Novo said expiring patents in some international markets pose a challenge, Lilly’s Ricks said tirzepatide should be protected into “the back half of the 2030s” in major markets. 

Risinger noted that Lilly is still working to drive global uptake for tirzepatide, which won U.S. approval for obesity in 2023. 

All eyes on pills

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.

Advertisement

George Frey | Bloomberg | Getty Images

Novo Nordisk is first to market with a GLP-1 pill for obesity, and it hit 50,000 weekly prescriptions in just under three weeks of its launch. But investors are watching to see how that shifts once Lilly’s pill rolls out to patients later this year. 

In an interview with CNBC’s “Mad Money,” Novo CEO Mike Doustdar said he’s confident about the company’s ability to compete with Lilly. 

“Clearly we have the most efficacious weight-reduction pill that there is and I’m very optimistic and bullish on when they come with their pill and we have to battle this out,” Doustdar said. 

Advertisement

He’s referring to clinical trial data suggesting that Novo’s Wegovy pill promotes comparable weight loss to its injectable counterpart, which is around 15%. Meanwhile, Lilly’s pill appears to be slightly less effective than that, based on separate study data. 

Risinger said the launch of Novo’s pill has benefited from the fact that the company is leveraging the Wegovy brand name, which is recognizable by many patients, and immediately launched direct-to-consumer advertising for the product in early January. 

But he said Lilly could capitalize on its pill’s convenience advantage. 

Orforglipron is a small-molecule drug that is absorbed more easily in the body and doesn’t require dietary restrictions like Novo Nordisk’s pill, which is a peptide medication. Patients are supposed to drink no more than four ounces of water with the Wegovy pill and must wait 30 minutes before eating or drinking anything else each day. 

Advertisement

Novo contends that those requirements won’t hinder uptake, but Risinger said it could help Lilly’s pill eventually generate greater sales globally. 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Nightingale Land plans 85 homes in Congleton

Published

on

Business Live

Site neighbours land where another developer is planning 120 homes

An outline application has been submitted for 85 homes on land south of Sandbach Road at Congleton

An outline application has been submitted for 85 homes on land south of Sandbach Road, Congleton (Image: FPCR Environment & Design)

Plans have been submitted for up to 85 homes in the open countryside at Congleton on fields next to land where 120 dwellings are also proposed.

Advertisement

Nightingale Land has applied for outline permission to bulldoze existing farm outbuildings on the site south of Sandbach Road and build up to 85 homes, including 30 per cent affordable.

It is next to land which is the subject of a separate planning application from Richborough Estates for up to 120 homes.

The Richborough application has not yet been determined by the council.

A planning statement submitted by Lane Town Planning on behalf of the Nightingale Land application, states: “The scheme could accommodate a range of house sizes and types in accordance with the council’s strategic housing market assessment.”

Advertisement

It adds that, as a direct consequence of the pre-application consultation exercises, the proposed development has been reduced from 100 homes to 85 homes.

Access to the new site is proposed from Sandbach Road by way of a priority junction.

The document says the scheme would include significant areas of public open space and the retention and enhancement of natural habitat around the existing hedgerow areas as well as orchard tree planting.

It would also include an equipped children’s play area, trim trails and play features along walking routes within green corridors.

Advertisement

Existing public rights of way crossing the site would also be retained and there would be new walking paths around the site.

The planning document states: “Market dwellings will be delivered by private house builders, with affordable housing either provided by, or in partnership with, a registered provider.

“Following a grant of consent, the site would be marketed immediately and sold as expeditiously as possible to one or more house builders who would submit the requisite reserved matters application(s).”

It adds it is anticipated the development of the site would take around 3.3 years to complete.

Advertisement

At the time of writing there has been one objection posted on the planning portal on Cheshire East Council’s website.

The objector says: “This proposal follows a recent application for 120 houses in the same vicinity, which would result in a cumulative total of approximately 200 new dwellings.

“If approved, this would have severe adverse impacts on local traffic, biodiversity, green infrastructure, and the character of the area.”

The application, number 26/0303/OUT, can be viewed on the planning portal on the council’s website.

Advertisement

The last date for submitting comments is March 12.

Continue Reading

Business

Form 13G Templeton Emerging Markets Fund For: 25 February

Published

on


Form 13G Templeton Emerging Markets Fund For: 25 February

Continue Reading

Business

Tesco to cut 180 jobs within its head office

Published

on

Tesco to cut 180 jobs within its head office

Chief executive Ken Murphy says Tesco must be “efficient and agile” to compete.

Continue Reading

Business

Ingredient that replaces eggs receives kosher certification

Published

on

Ingredient that replaces eggs receives kosher certification

Umami United offers ProBake Binder.

Continue Reading

Business

Coupang (CPNG) Stock Dips to $18.59 Ahead of Q4 2025 Earnings, Analysts Eye Regulatory Risks

Published

on

Coupang

Coupang Inc.’s shares traded near $18.59 on February 24, 2026, down modestly amid investor caution over potential regulatory scrutiny in Korea and the United States, as well as costs from its Taiwan expansion, with the e-commerce giant set to report fourth-quarter 2025 results on February 26.

Coupang
Coupang

As of February 24, 2026, Coupang (NYSE: CPNG) closed at $18.59, up 0.05% on the day after fluctuating in a range of $17.66 to $18.74 with volume of approximately 26.1 million shares. The stock has declined about 5-6% over the past week and remains well below 2025 highs near $34, reflecting a year-to-date pullback in 2026. Market capitalization hovers around $33-34 billion.

The recent pressure stems from broader concerns in the Korean internet sector and U.S. political dynamics. On February 24, shares slipped as investors weighed whether Coupang could become a bargaining chip in potential trade talks, following interim CEO Harold Rogers’ closed-door deposition before the U.S. House Judiciary Committee on February 23. Regulatory investigations tied to a November 2025 data breach have also weighed on sentiment, contributing to share weakness.

Coupang is scheduled to release Q4 2025 earnings after market close on February 26, with a conference call at 5:30 p.m. ET. The Zacks consensus estimates revenue of $9.14 billion—up 14.78% year-over-year—while projecting EPS of $0.02, down 50% from the year-ago quarter. The earnings mark has declined slightly in recent weeks, signaling caution around profitability pressures from international growth and the data breach fallout.

The company has expanded aggressively into Taiwan, with costs contributing to margin compression in recent periods. Analysts note that while revenue growth remains solid—driven by core South Korean operations, Rocket Delivery, and e-commerce momentum—profitability faces headwinds from these investments. Q3 2025 results showed EPS of $0.05 on $9.3 billion in revenue, beating expectations, but Q4 guidance and commentary will be key to assessing the Taiwan trajectory.

Advertisement

On the analyst front, views are mixed. UBS lowered its price target to $25 from $35 on February 19, 2026, while maintaining a Buy rating, citing regulatory scrutiny as a drag. Bernstein initiated coverage on February 5 with an Underperform rating and $17 target, reflecting caution in the Korean internet space. Consensus among 11 analysts leans Hold to Moderate Buy, with average 12-month price targets around $27.70—implying about 49% upside from current levels. High targets reach $40, low ends around $17.

Coupang’s core business benefits from strong market position in South Korea, with high customer loyalty through fast delivery and membership perks. The company continues investing in logistics, private-label products, and international markets to diversify beyond domestic reliance. Recent small-business initiatives, such as helping Pennsylvania companies expand globally via Coupang, highlight efforts to strengthen ecosystem ties.

Risks include competitive intensity from local and global players, potential trade policy impacts, and execution on profitability amid expansion costs. The data breach investigations add uncertainty, though management has emphasized containment and customer protection.

The February 26 earnings release will provide critical updates on revenue trends, margin progress, Taiwan performance, and 2026 guidance. Positive surprises on subscriber growth or cost controls could spark a rebound; signs of prolonged pressure might extend downside.

Advertisement

Coupang remains a key player in Asian e-commerce, with its logistics network and customer-centric model offering long-term potential. As the company navigates regulatory and expansion challenges, investor focus will center on proving sustainable profitability in 2026.

Continue Reading

Business

Sports village and hundreds of homes planned for Preston development

Published

on

Business Live

Backers aim to create ‘high-quality’ hub for ‘local grassroots sport’

Longridge Town FC ground

Longridge Town FC’s ground(Image: Levitt Bernstein, via Preston City Council planning portal)

More than 200 homes and a raft of new and upgraded sports facilities could be created on the outskirts of Preston as part of a major residential and leisure development.

Advertisement

The proposed Longridge Sports Village scheme would provide a “high-quality” hub for “local grassroots sport”, according to the organisations behind it.

Provision for football, gymnastics, padel and informal runs would sit alongside up to 220 new dwellings, all which would fall into the discounted ‘affordable homes’ category. More than 40 of the proposed properties are flats designed specifically for older people.

A 12-hectare site to the north west of the town has been earmarked for the project, adjacent to Longridge Town Football Club and Longridge Cricket Club.

Plans for the site – bounded by Inglewhite Road and Chipping Lane – first emerged last year when a public consultation was carried out into an initial blueprint.

Advertisement

Now, Longridge-based Steel Work Construction and Preston social housing provider Community Gateway Association have submitted an outline proposal to Preston City Council, seeking planning permission for the project – which they say will plug “a recognised deficit in local sports provision”.

Their joint application sets out the specifics of the sporting plans, which include the creation of a seven-a-side 3G football pitch to serve the needs of Longridge Town’s junior club and the 300 players that make up its 20 teams. The facility would, it is claimed, put an end to the weather-related cancellations that beset the junior fixtures during winter – and would also be used by the senior team for training.

The existing grass pitch for the first team would be retained, with the clubhouse extended and improvements made for spectators.

Elsewhere, four covered padel courts are planned – for which there was “strong local support” expressed in last year’s public consultation, the application states.

Advertisement

Meanwhile a permanent, purpose-built base is proposed for Longridge Gymnastics Club, which is currently forced to operate from rented facilities four miles out of town in Ribbleton.

A 1.5km “recreational running and walking route” also forms part of the plans – a facility that would be “integrated into the site’s network of green spaces for the benefit of the whole community”.

The plot sits in the open countryside, making it a location that would not usually be deemed suitable for significant development. However, the planning statement accompanying the sports village proposal stresses that it is not a “remote, isolated landscape”.

It adds that the surrounding area has become “an established focus for the town’s recent residential growth”, with planning permissions granted for new housing along Halfpenny Lane, Inglewhite Road, and Chipping Lane – making the sports village site “a logical and sustainable extension of the built-up area, rather than an intrusion into undeveloped countryside”.

Advertisement

Meanwhile, an odour assessment undertaken on behalf of the applicants concluded there was only a “slight and not significant” risk of smells from the nearby pig farming operation at Belmont Farm affecting future residents and leisure users.

The proximity of the piggery was highlighted by the city council last year when it considered – and decided against – requiring an environmental impact assessment as part of the planning application for the sports village.

The assessment found that the southernmost parts of the site would be most affected by odours – and so that zone will not be used for residential development.

Advertisement
Continue Reading

Business

River Point Farms adds to onion portfolio

Published

on

River Point Farms adds to onion portfolio

Individually quick-frozen line joins company’s fresh pack and fresh-cut offerings. 

Continue Reading

Business

Co-founders launch espresso soda startup

Published

on

Co-founders launch espresso soda startup

Esspo is formulated with 120 mg of caffeine, 240 mg of L-Theanine. 

Continue Reading

Business

CleanSpark (CLSK) Stock Surges 5.4% to $10.35 on AI Pivot Momentum, Despite Q1 2026 Loss Widening

Published

on

CleanSpark Inc

CleanSpark Inc.’s stock rallied 5.4% to close at $10.35 on February 24, 2026, rebounding from recent pressure as investors focused on the company’s strategic shift toward high-performance computing (HPC) and AI infrastructure, even after reporting a wider-than-expected net loss in fiscal first-quarter 2026 results released earlier in February.

CleanSpark Inc
CleanSpark Inc

As of February 24, 2026, CleanSpark (NASDAQ: CLSK) traded in a session range of $9.59 to $10.60 with volume exceeding 25.9 million shares, reflecting heightened activity amid the recovery. Pre-market trading on February 25 pushed shares higher to around $10.56-$10.63, suggesting continued interest. The shares have shown volatility year-to-date in 2026 but remain elevated from 2025 lows, with a 52-week range spanning lower levels to recent peaks near $23 in prior periods. Market capitalization hovers around $2.5 billion to $3 billion, depending on intraday moves.

The February 24 gain came despite a challenging Q1 fiscal 2026 earnings report on February 5, 2026 (for the quarter ended December 31, 2025). CleanSpark posted revenue of $181.2 million, up 11.6% year-over-year but missing analyst estimates of around $194 million. The company reported a net loss of $378.7 million—significantly wider than prior periods—and an EPS of -$1.35, far below consensus forecasts of $0.09 to $0.26. Gross margins contracted to 47% from 57% year-over-year, reflecting higher operational costs during the transition.

Management attributed the miss to reduced Bitcoin mining contributions amid price volatility and investments in HPC infrastructure. However, executives emphasized progress in securing AI data center leases, with the first expected soon. The pivot positions CleanSpark to capitalize on surging demand for compute power, leveraging its sustainable energy model and existing facilities.

Analysts maintain a cautiously optimistic view. Consensus among 12-14 firms rates CLSK a Moderate Buy to Strong Buy, with average 12-month price targets around $19.19 to $20.60—implying 85-100% upside from the February 24 close. Sanford C. Bernstein raised its target to $24 from $20 in late 2025, maintaining an Outperform rating. Other updates include Chardan Capital lowering to $16 from $30 in early February 2026 while keeping a Buy, and Keefe, Bruyette & Woods reducing to $14 from $18 but staying Outperform. Wall Street Zen shifted to Sell in November 2025, citing execution risks.

Advertisement

The company continues expanding its fleet, with operational updates highlighting increased hashrate and energy efficiency. January 2026 metrics showed progress toward targets, though Bitcoin exposure remains a volatility driver. CleanSpark’s focus on low-cost, sustainable power differentiates it in the competitive mining and HPC landscape.

Upcoming catalysts include the next earnings report for fiscal Q2 2026, estimated around May 7, 2026. Analysts project an EPS of around -$0.25 to -$0.38 and revenue near $164 million. Investors will scrutinize HPC lease announcements, margin trends, cost controls, and guidance revisions amid the AI infrastructure boom.

CleanSpark navigates a transitional phase, balancing legacy Bitcoin mining with emerging HPC opportunities. While Q1 results highlighted profitability challenges during the shift, the AI pivot and analyst upside targets support optimism for recovery. With shares rebounding and trading at levels offering substantial potential if execution improves, CleanSpark remains a high-beta play in the digital asset and compute sector.

Advertisement
Continue Reading

Business

Opinion: Gas up for energy insurance role

Published

on

Opinion: Gas up for energy insurance role

OPINION: The flexibility of gas cements its value as a transitional energy source.

Continue Reading

Trending

Copyright © 2025